Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial.

PubWeight™: 1.58‹?› | Rank: Top 4%

🔗 View Article (PMID 12681866)

Published in Obstet Gynecol on April 01, 2003

Authors

Leslie Miller1, James P Hughes

Author Affiliations

1: Departments of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA. lmiller@u.washington.edu

Articles citing this

Targeting temporomandibular disorder pain treatment to hormonal fluctuations: a randomized clinical trial. Pain (2011) 1.42

Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab (2007) 1.02

Therapeutic amenorrhea in patients at risk for thrombocytopenia. Obstet Gynecol Surv (2008) 0.92

Contraception in Canada: a review of method choices, characteristics, adherence and approaches to counselling. CMAJ (2007) 0.87

Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can (2004) 0.87

Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag (2008) 0.81

Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Prefer Adherence (2009) 0.81

A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception (2011) 0.79

Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians. Eur J Contracept Reprod Health Care (2015) 0.77

New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control. Int J Womens Health (2010) 0.76

Menstrual suppression: current perspectives. Int J Womens Health (2014) 0.76

Continuous use of oral contraceptives reduces bleeding. J Fam Pract (2003) 0.75

Articles by these authors

(truncated to the top 100)

Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials (2006) 7.50

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35

Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23

Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med (2005) 3.96

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48

Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19

HIV serosorting in men who have sex with men: is it safe? J Acquir Immune Defic Syndr (2008) 2.91

HIV-1, sexually transmitted infections, and sexual behavior trends among men who have sex with men in Lima, Peru. J Acquir Immune Defic Syndr (2007) 2.71

Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51

Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA (2002) 2.37

Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36

Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis (2009) 2.26

Male circumcision, religion, and infectious diseases: an ecologic analysis of 118 developing countries. BMC Infect Dis (2006) 2.10

Prevalences of sexually transmitted infections in young adults and female sex workers in Peru: a national population-based survey. Lancet Infect Dis (2012) 2.03

Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr (2010) 2.01

Development and performance of a microwell-plate-based polymerase chain reaction assay for Mycoplasma genitalium. Sex Transm Dis (2003) 1.99

Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol (2003) 1.91

Handheld computers for self-administered sensitive data collection: a comparative study in Peru. BMC Med Inform Decis Mak (2008) 1.82

Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet (2012) 1.80

Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis (2012) 1.78

Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health (2007) 1.78

Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis (2012) 1.67

Sentinel surveillance of sexually transmitted infections/HIV and risk behaviors in vulnerable populations in 5 Central American countries. J Acquir Immune Defic Syndr (2007) 1.63

HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med (2013) 1.59

Correlates of national HIV seroprevalence: an ecologic analysis of 122 developing countries. J Acquir Immune Defic Syndr (2004) 1.59

An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr (2013) 1.55

HIV testing frequency among men who have sex with men attending sexually transmitted disease clinics: implications for HIV prevention and surveillance. J Acquir Immune Defic Syndr (2009) 1.55

Clandestine induced abortion: prevalence, incidence and risk factors among women in a Latin American country. CMAJ (2009) 1.55

Using nurses to identify HAART eligible patients in the Republic of Mozambique: results of a time series analysis. Hum Resour Health (2007) 1.51

Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection. Clin Infect Dis (2004) 1.50

Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48

Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. Sex Transm Dis (2012) 1.41

Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis (2003) 1.36

Higher concentration of HIV RNA in rectal mucosa secretions than in blood and seminal plasma, among men who have sex with men, independent of antiretroviral therapy. J Infect Dis (2004) 1.35

Quality of HIV care provided by non-physician clinicians and physicians in Mozambique: a retrospective cohort study. AIDS (2010) 1.28

Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique. J Acquir Immune Defic Syndr (2011) 1.27

Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis (2007) 1.27

Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS One (2013) 1.26

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24

Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev (2010) 1.21

Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis (2009) 1.18

Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev (2010) 1.18

Discrete proportional hazards models for mismeasured outcomes. Biometrics (2003) 1.17

An assessment of the accuracy and availability of data in electronic patient tracking systems for patients receiving HIV treatment in central Mozambique. BMC Health Serv Res (2012) 1.12

Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration. Am J Epidemiol (2013) 1.11

Influence of study population on the identification of risk factors for sexually transmitted diseases using a case-control design: the example of gonorrhea. Am J Epidemiol (2004) 1.10

Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. J Infect Dis (2009) 1.09

Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis (2008) 1.09

Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr (2013) 1.09

Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis (2011) 1.08

Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One (2011) 1.08

Determinants of cervical cancer rates in developing countries. Int J Cancer (2002) 1.08

An evaluation of HIV partner counseling and referral services using new disposition codes. Sex Transm Dis (2009) 1.08

Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol (2009) 1.06

Male circumcision and risk of HIV acquisition among MSM. AIDS (2011) 1.06

Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis (2009) 1.05

Applications of continuous time hidden Markov models to the study of misclassified disease outcomes. Stat Med (2003) 1.03

Estimating duration in partnership studies: issues, methods and examples. Sex Transm Infect (2010) 1.02

Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters. AIDS Res Hum Retroviruses (2013) 1.02

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol (2011) 1.01

Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial. BMC Public Health (2010) 1.00

Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99

Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064). AIDS Patient Care STDS (2014) 0.99

Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis (2012) 0.96

Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev (2002) 0.96

Evaluation of dry and wet transport of at-home self-collected vaginal swabs for human papillomavirus testing. J Med Microbiol (2012) 0.95

Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis (2010) 0.93

A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. AIDS Behav (2011) 0.93

Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study. J Womens Health (Larchmt) (2014) 0.91

Age of diagnosis of squamous cell cervical carcinoma and early sexual experience. Cancer Epidemiol Biomarkers Prev (2009) 0.90

Evaluation of a population-based program of expedited partner therapy for gonorrhea and chlamydial infection. Sex Transm Dis (2007) 0.90

Sexual intercourse and risk of symptomatic urinary tract infection in post-menopausal women. J Gen Intern Med (2008) 0.89

Age- and gender-specific estimates of partnership formation and dissolution rates in the Seattle sex survey. Ann Epidemiol (2010) 0.89

Viral load and short-term natural history of type-specific oncogenic human papillomavirus infections in a high-risk cohort of midadult women. Int J Cancer (2013) 0.89

Characterization of IgA response among women with incident HPV 16 infection. Virology (2003) 0.89

Characteristics of multiple and concurrent partnerships among women at high risk for HIV infection. J Acquir Immune Defic Syndr (2014) 0.89

Expedited partner therapy: a robust intervention. Sex Transm Dis (2010) 0.88

Circumcision and acquisition of human papillomavirus infection in young men. Sex Transm Dis (2011) 0.87

Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr (2017) 0.87

Trends in Serosorting and the Association With HIV/STI Risk Over Time Among Men Who Have Sex With Men. J Acquir Immune Defic Syndr (2016) 0.86

Modeling breastmilk infectivity in HIV-1 infected mothers. Biometrics (2003) 0.86

Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. J Clin Virol (2005) 0.86

Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. J Acquir Immune Defic Syndr (2013) 0.85

A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials. Biostatistics (2012) 0.84

Summary measures of adherence using pill counts in two HIV prevention trials: the need for standardisation in reporting. AIDS Behav (2013) 0.83

Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J Clin Endocrinol Metab (2007) 0.83

Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstet Gynecol (2008) 0.83

Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission. PLoS One (2012) 0.82

Chlamydia screening coverage estimates derived using healthcare effectiveness data and information system procedures and indirect estimation vary substantially. Sex Transm Dis (2013) 0.82

Factors associated with oropharyngeal human immunodeficiency virus shedding. J Infect Dis (2003) 0.82

Disclosure of genital human papillomavirus infection to female sex partners by young men. Sex Transm Dis (2012) 0.81

Challenges in the design of HIV prevention trials in the United States. J Acquir Immune Defic Syndr (2010) 0.80

Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. Antimicrob Agents Chemother (2012) 0.80

Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr (2017) 0.80

Oncogenic Human Papillomavirus Infections in 18- to 24-Year-Old Female Online Daters. Sex Transm Dis (2015) 0.78

Non-monogamy and risk of infection with Chlamydia trachomatis and Trichomonas vaginalis among young adults and their cohabiting partners in Peru. Sex Transm Infect (2010) 0.78

Nonparametric and Semiparametric Analysis of Current Status Data Subject to Outcome Misclassification. Stat Commun Infect Dis (2010) 0.77